| Study |
|
Exclusion reasons |
Remarks |
Reference(s) |
|
|
CheckMate 511, 2019
|
randomized controlled trial
|
|
phase IIIb/IV
|
|
|
|
Wolchok, 2010
|
-
|
inadequate or absent control group
|
|
Wolchok Lancet Oncol. 2010; 11:155-64 10.1016/S1470-2045(09)70334-1 Wolchok Ann. Oncol. 2013; 24:2174-80 10.1093/annonc/mdt161
|
|
|
Amaria, 2018
|
-
|
inadequate or absent control group
|
|
Amaria Nat. Med. 2018; 24:1649-1654 10.1038/s41591-018-0197-1
|
|
|
Hersh, 2011
|
-
|
inadequate or absent control group
|
|
Hersh Invest New Drugs 2011; 29:489-98 10.1007/s10637-009-9376-8
|
|
|
Tarhini, 2019
|
-
|
inadequate or absent control group
|
|
Tarhini Clin. Cancer Res. 2019; 25:524-532 10.1158/1078-0432.CCR-18-2258
|
|
|
Long, 2018
|
-
|
not relevant exposure
|
|
Long Lancet Oncol. 2018; 19:672-681 10.1016/S1470-2045(18)30139-6
|
|
|
Blank, 2018
|
-
|
not relevant study design
|
|
Blank Nat. Med. 2018; 24:1655-1661 10.1038/s41591-018-0198-0
|
|
|
Long, 2018
|
-
|
not relevant study design
|
|
Long Lancet Oncol. 2018; 19:672-681 10.1016/S1470-2045(18)30139-6
|
|
|
Lebbé, 2019
|
-
|
not relevant outcome
|
|
Lebbé J. Clin. Oncol. 2019; 37:867-875 10.1200/JCO.18.01998
|
|
|
OpACIN-neo, 2019
|
-
|
not relevant outcome
|
|
Rozeman, E.A. The Lancet Oncology 2019; 20:948-. 10.1016/S1470-2045(19)30151-2
|
|
